The Save the Children Immunisation Accelerator has opened a second round of applications, inviting organisations in Nigeria and Ethiopia to submit proposals for innovations that tackle entrenched ...

Testosterone plays a critical role in male sexual functioning but can also impact bone mass, fat distribution, muscle mass, ...

Neurofibromatosis Type 2 Market Insight, Epidemiology and Market Forecast - 2034The Neurofibromatosis Type 2 treatment market is experiencin ...

Anthropic has launched a powerful analytics dashboard for its Claude Code AI assistant, giving engineering leaders real-time insights into developer productivity, tool usage, and ROI on AI coding ...

AWS beleives AI agents will change how enterprises work and with its new Amazon Bedrock AgentCore, it hopes to make it easier ...

This summary highlights significant events in the health sector, including Johnson & Johnson's profit boost from Darzalex, safety concerns for GSK's cancer drug, refugee malnutrition in Gaza, KKR's ...

After posting a double beat for Q2 2025, J&J (NYSE:JNJ), the pharma sector’s bellwether for the earnings season, added ~6% on Wednesday, marking its biggest intraday gain in nearly two years and ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

GSK PLC closed 15.32% short of its 52-week high of £16.79, which the company reached on September 9th.

UK pharma major GSK is seeking US approval for Blenrep (belantamab mafodotin) in two multiple myeloma indications.

The U.S. Food and Drug Administration's reviewers on Wednesday raised efficacy concerns over the use of Otsuka Pharma's drug in combination with Viatris' Zoloft for the treatment of adults with PTSD.